OncoPharm

Cannabinoids appear to impact immune system function, so could cannabis use blunt the effect of immune checkpoint inhibitors? I don't know, brah. Maybe?

Review: https://pubmed.ncbi.nlm.nih.gov/?term=35749680

Cannabis associated with poorer ORR: https://doi.org/10.1634/theoncologist.2018-0383

Cannabis associated with poorer TTP & OS: https://doi.org/10.3390/cancers12092447

Ide-Cel vs. "standard" treatment in relapsed/refreactory multiple myeloma study - the KarMMa-3 trial - is discussed.

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2213614

CodeBreak200: docetaxel vs. sotorasib in 2nd-line metastatic NSCLC (KRAS-G12C). A new safety signal emerges.

https://doi.org/10.1016/S0140-6736(23)00221-0

A new survival prediction model for elderly patients with AML not receiving intensive therapy.

https://doi.org/10.1002/cncr.34609

First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib.

Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.

Tucatinib's FDA-approval (with trastuzumab) for HER2 amplified metastatic colorectal cancer launches a new era of targeted therapy in colorectal cancer.

Targeting HER2 (amplified in ~3-5% of advanced colorectal cancers) in colorectal cancer will likely evolve over the coming years, so a brief history on how it has evolved so far may be helpful.

The Landmarks in OncoPharm series returns to discuss adjuvant interferon in melanoma.

ECOG 1684: https://pubmed.ncbi.nlm.nih.gov/?term=36649675

Commentary on E1684: https://ascopubs.org/doi/abs/10.1200/JCO.22.02354

Broad, big picture overview of breast cancer and its treatment.

Ambitious.

Do not recommend listening at 1.5x

New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma.

And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116

This gift-giving season, we ask whether we want to Keep, Re-gift, or Return new oncology drugs approved this past year.

The FDA's pilot program, project renewal, uses capecitabine for its first label makeover. What's new & what are the possible implications of the DPYD warning now in the prescribing information?